Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07134413) titled 'QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC' on Aug. 14.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Guangdong Association of Clinical Trials
Condition:
NSCLC
Intervention:
Drug: QL1706 plus bevacizumab with or without chemotherapy
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: August 2025
Target Sample Size: 77
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07134413
Published by HT Digital Cont...